Peptydy na spalanie tłuszczu — AOD-9604, MOTS-C | PEPTEX
Opublikowano: 2026-04-12 16:00:00 | PEPTEX Research
✓ Reviewed by: Eskina Yulia — Endocrinologist · April 2026
Fat burning and weight loss are different processes often confused. Weight loss means reducing body mass — including water, glycogen and muscle. Fat burning is targeted oxidation of triglycerides from adipose tissue while preserving metabolically active muscle. A classic caloric deficit delivers 0.5–1% fat loss per week, but after 3–4 months metabolism adapts and the plateau becomes unbeatable. Fat-burning peptides work not through appetite suppression but directly — triggering lipolysis, accelerating mitochondrial beta-oxidation and activating brown adipose thermogenesis. At PEPTEX we see this approach producing results without the yo-yo effect.
Fat burning vs weight loss — the difference
The scale shows total mass, not body composition. A 5 kg loss can include 2 kg fat, 1.5 kg muscle and 1.5 kg water, dropping basal metabolism by 80–120 kcal/day. Fat burning focuses on reducing adipose tissue (measured by % body fat via DEXA or BIA), while muscle is preserved or even grows. Peptide protocols are therefore judged not only by kilograms but by waist circumference, muscle/fat ratio, and biomarkers — leptin, adiponectin, fasting insulin.
An important marker of quality fat loss is reduction of visceral fat, directly tied to cardiovascular risk. Tesamorelin and GLP-1 agonists lead on this parameter. See our GLP-1 weight loss guide for deeper analysis.
Three biochemical pathways: lipolysis, beta-oxidation, thermogenesis
Fat burning is a three-step chain; failure at any stage nullifies the process. Lipolysis breaks triglycerides into free fatty acids (FFA) and glycerol via hormone-sensitive lipase (HSL) and ATGL. Triggered by catecholamines, GH, and peptides like AOD-9604 through beta-3 adrenergic receptors (PubMed 22584800). Beta-oxidation transports FFAs into mitochondria via the carnitine shuttle, breaking them down to acetyl-CoA feeding the Krebs cycle, regulated by AMPK and mitochondrial density (PubMed 21487133). Thermogenesis converts chemical energy into heat in brown fat via UCP1, activated by cold, caffeine and tesamorelin.
Why diets plateau
After 3–4 months of deficit, leptin drops 40–60%, T3 falls 20–30%, resting metabolism slows 5–10%. This is adaptive thermogenesis. Peptides bypass these mechanisms: AOD-9604 drives lipolysis directly; MOTS-C activates AMPK and renews mitochondria.
The insulin resistance factor
High fasting insulin blocks HSL and halts lipolysis. Dropping fasting insulin from 15 to 6 µU/ml doubles overnight fat burning. MOTS-C and 5-Amino-1MQ help here.
AOD-9604 — a classic GH fragment for lipolysis
AOD-9604 is a synthetic peptide representing the C-terminal fragment (amino acids 177–191) of growth hormone with an added tyrosine. Developed in the early 2000s as an anti-obesity drug. Unlike full GH, AOD-9604 does not raise IGF-1, cause fluid retention, or affect glucose while retaining lipolytic activity (PubMed 11602048).
In a 12-week phase 2 trial, AOD-9604 1 mg/day produced 2.6x more weight loss than placebo, primarily from abdominal fat (PubMed 17956598). Practical protocol: 300 mcg subcutaneous, fasted morning, 30 min before cardio, 5–6 days/week, 8–12 week cycle. Expected outcome: 3–5% fat loss with muscle preservation.
Receptor-level mechanism
AOD-9604 upregulates beta-3 adrenergic receptor expression in adipocytes by 40–60%, sensitizes HSL to catecholamines and raises baseline lipolysis 2–3x.
Best fit profiles
Athletes cutting, individuals with stubborn abdominal fat post-diet, clients 35+ with declining GH. See our honest AOD-9604 review and AOD-9604 vs tirzepatide comparison.
| Parameter | AOD-9604 | Full GH |
|---|---|---|
| Lipolysis | Yes, strong | Yes |
| IGF-1 rise | No | Yes (cancer risk) |
| Water retention | No | Yes |
| Glucose effect | Neutral | Elevates |
| Side effects | Minimal | Multiple |
| Cycle cost | Moderate | High |
MOTS-C — mitochondrial peptide, AMPK activator
MOTS-C (Mitochondrial Open Reading frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015 by Lee and colleagues (PubMed 25738459). Its main function is AMPK activation — the cell's metabolic master switch, toggling from energy storage to expenditure (PubMed 26626483).
Practically: MOTS-C increases insulin sensitivity by 25–40%, boosts muscle fatty acid beta-oxidation, stimulates mitochondrial biogenesis (PGC-1α). Protocol: 5–10 mg subcutaneous 2–3x/week, 8–12 week cycle. Expected: 2–4% fat loss, endurance gains, HbA1c drop of 0.3–0.5%. Deep-dives: MOTS-C and metabolism and mitochondria-aging connection.
5-Amino-1MQ — NNMT inhibitor
5-Amino-1-methylquinolinium is a small molecule inhibiting nicotinamide-N-methyltransferase (NNMT), which is expressed 2–3x higher in obese adipose tissue. Blocking NNMT raises NAD+ in adipocytes and increases energy expenditure (PubMed 29773825).
In mouse models 5-Amino-1MQ reduced body mass by 14% with no diet change. In practice: 50–150 mg oral daily morning, 8–12 week cycle. Selectivity for adipose tissue without muscle impact. Pairs well with AOD-9604.
Tesamorelin for visceral fat
Tesamorelin is a stabilized GHRH analog (44 amino acids) stimulating pituitary GH release. FDA-approved for HIV-associated visceral fat and widely used in metabolic practice.
In phase 3, tesamorelin 2 mg/day for 26 weeks reduced visceral fat by 15.2% (PubMed 19734430). Meta-analysis confirms a sustained 15–20% reduction with lipid profile improvement (PubMed 27416104). Protocol: 1–2 mg evening subcutaneous, 5 days/week, 12–26 week cycle. Details in tesamorelin vs CJC-1295 and ipamorelin + tesamorelin stack.
GLP-1 peptides for fat burning — their role
GLP-1 agonists — tirzepatide, semaglutide, retatrutide — reduce body mass 15–22.5% in 68–72 weeks via appetite suppression and gastric emptying delay (PubMed 33567185, PubMed 35658024). But 25–40% of lost mass is muscle. Adjunct direct fat-burning peptides — AOD-9604 and MOTS-C — protect muscle and enhance fat-specific oxidation.
Full breakdown in the GLP-1 guide, tirzepatide vs retatrutide in a dedicated comparison, and muscle/skin protection on GLP-1 in GHK-Cu + GLP-1.
Comparative table of fat-burning peptides
| Peptide | Mechanism | Fat loss (12w) | Appetite | Visceral fat | Cost |
|---|---|---|---|---|---|
| AOD-9604 | Lipolysis via B3-AR | 3–5% | Neutral | Moderate | $$ |
| MOTS-C | AMPK / mitochondria | 2–4% | Neutral | Moderate | $$ |
| 5-Amino-1MQ | NNMT inhibitor | 3–5% | Neutral | Moderate | $$$ |
| Tesamorelin | GHRH / GH rise | 5–8% (visc.) | Neutral | Strong | $$$ |
| Tirzepatide | GLP-1 / GIP | 15–20% | Strong suppression | Strong | $$$$ |
| Retatrutide | GLP-1/GIP/glucagon | 20–24% | Strong suppression | Very strong | $$$$ |
Ready stacks for typical goals
| Goal | Stack | Duration | Expected result |
|---|---|---|---|
| Athlete cut | AOD-9604 300 mcg/day + MOTS-C 10 mg 3x/wk | 10 weeks | -4–6% fat, muscle preserved |
| Abdominal fat 40+ | Tesamorelin 2 mg/day + AOD-9604 300 mcg | 16 weeks | -18% visceral fat |
| Obesity + resistance | Tirzepatide + MOTS-C + GHK-Cu | 24 weeks | -15–20% mass, skin protection |
| Metabolic syndrome | MOTS-C + 5-Amino-1MQ | 12 wee... PEPTEX dostarcza do Polski — szybka wysyłka, certyfikowana jakość, darmowa dostawa od 150 €. Czytaj więcej: Peptydy na spalanie tłuszczu — AOD-9604, MOTS-C | PEPTEXArticlesВведите корректный email
Введите имя и фамилию
▾
Get in touchChoose how you'd like to reach us
or email us
🎁
Special offer for youEnter your email and get 15% off your first order 🪙 Оплата криптовалютойШаг 1 из 2 — выберите валюту
Dosage Calculator
1
Loading...
💬
SupportChoose a convenient way to contact us Проверка подлинностиВведите серийный код с упаковки
0
Задания
⏳
⏳
FAQ⏳
|
💬 Комментарии